GLP-1 Market Report 2026: Oral Pills, New Approvals, and What’s Next

The GLP-1 market entered 2026 in a different era. Three products won FDA approval in quick succession: oral Wegovy in December 2025, a higher-dose Wegovy injection in March 2026, and Foundayo (orforglipron) in April 2026. Pills are now the central battleground between Novo Nordisk and Eli Lilly, the market is on track to grow from roughly $18 billion in 2026 toward more than $30 billion by 2030 by several estimates, and a deep pipeline of next-generation molecules is moving through late-stage trials. Here’s the state of play.

The shift to pills

For years, effective GLP-1 treatment meant injections. That assumption broke in early 2026. Oral Wegovy launched in January and saw rapid uptake, capturing about a third of new-to-brand prescriptions within roughly eight weeks, with most of that volume flowing through cash-pay channels. The more telling number: around two-thirds of those starting it were new to GLP-1 therapy altogether. That suggests pills are expanding the market, not just shuffling patients off injections, by pulling in people who avoided treatment because of needles, cost, or cold-chain hassle. Foundayo’s April approval opened a second front, giving Lilly an oral entry against Novo’s pill.

The 2026 approvals at a glance

Three approvals reset the competitive map. Oral Wegovy (semaglutide 25 mg) became the first oral GLP-1 cleared specifically for weight management, delivering roughly 14 to 17% weight loss depending on how it’s measured. Wegovy HD (semaglutide 7.2 mg injection) arrived in March as a higher-dose option for people who tolerated the standard dose, pushing mean weight loss past 20% in its trial. Foundayo (orforglipron) became Lilly’s second obesity drug and the first GLP-1 pill with no food or water restrictions, with about 11% weight loss and the convenience of any-time dosing.

Novo versus Lilly

The two leaders head into 2026 on diverging paths. Lilly guided to 2026 revenue of roughly $80 to $83 billion, a jump of about 25%, on the strength of its obesity and diabetes franchises and an early move into direct-to-consumer sales. Novo, facing falling U.S. prices and looming patent expirations in several large markets, warned of a sales decline. Lilly has taken a clear market-share lead, helped by more effective injectables, and analysts expect that gap to widen. Both companies are pouring money into manufacturing to scale oral and injectable supply.

Head-to-head data reshaping competition

Direct comparisons are increasingly settling debates that cross-trial guesswork could not. Tirzepatide beat semaglutide head-to-head in obesity, reaching about 20% versus roughly 14%. Among the oral pills, orforglipron outperformed oral semaglutide on blood sugar and weight in a large diabetes trial. And a closely watched comparison of CagriSema against tirzepatide showed CagriSema falling short of non-inferiority, with about 23% weight loss versus 25.5% for tirzepatide. These results are steering both prescribers and investors toward the strongest performers.

The pipeline

Behind the approved products sits a crowded development field. Retatrutide, Eli Lilly’s triple-hormone agonist, posted around 25% weight loss at its top dose in a large Phase 3 trial reported in mid-2026, among the highest figures seen to date. CagriSema, Novo’s semaglutide-plus-amylin combination, is under FDA review with a decision expected later in the year. Survodutide and amycretin are advancing through trials, and newer entrants from companies including Pfizer, AstraZeneca, Viking, and Structure Therapeutics are pushing additional oral and injectable candidates forward. It’s worth being clear that retatrutide, CagriSema, survodutide, and amycretin remain investigational. None is FDA-approved or available, including from TrimRx, and any product sold online as a research-use version of these molecules lacks the quality, sterility, and dosing oversight of approved medicine.

Market size and access

The numbers vary by how analysts define the category, but the direction is consistent. The weight-loss GLP-1 segment is estimated near $18 billion in 2026 and projected to climb past $30 billion by 2030 by one forecast, while broader estimates that include diabetes put the overall GLP-1 market well above $80 billion in 2026. By late 2025, roughly one in eight U.S. adults reported having taken a GLP-1 drug. Two forces could widen access further: cheaper, easier-to-distribute pills, and patent expirations in large markets like China, India, and Brazil that open the door to lower-cost options. For now, cash-pay remains a major channel, especially for the new oral products.

What it means for patients

For people considering treatment, the practical upshot is more choice and, in some cases, lower prices. Consider a scenario where someone put off treatment for years because of needles or a tight budget. The arrival of oral options at self-pay prices near $149 a month changes that calculation. The trade-off is that pills generally deliver somewhat less weight loss than the strongest injections, so the right choice still depends on individual goals and medical history.

To go deeper on what’s coming, our next-generation GLP-1 pipeline overview maps the candidates in development, and our look at survodutide versus tirzepatide compares two different mechanisms. If you’re focused on what you can actually get today, our guide to oral GLP-1 options in pill form covers the approved choices. To see whether a personalized program fits you, you can take the free TrimRx assessment quiz.

This article is for educational and informational purposes only and is not medical advice. Several medications discussed here are investigational, not FDA-approved, and not available, including from TrimRx. Market figures are estimates that vary by source. Always consult a licensed healthcare provider about treatment options suited to your individual situation.